From current status to optimization of HCV treatment

Recommendations from an expert panel

Antonio Craxì, Carlo Federico Perno, Mauro Viganò, Francesca Ceccherini-Silberstein, Salvatore Petta, AdHoc (Advancing Hepatitis C for the Optimization of Cure) Working Party, Savino Bruno

Research output: Contribution to journalArticle

Abstract

Chronic hepatitis C virus (HCV) infection is a major public health problem at a global level, causing an enormous burden of hepatic and extra-hepatic morbidity and mortality. Treatment of chronic HCV (CHC) has been revolutionized in the last few years by the introduction of highly effective and well tolerated direct acting antiviral agents (DAAs) able to achieve >90% rates of sustained virological response (SVR) in many groups of patients, including those previously excluded from interferon-based regimens. For such reason interferon-free regimens are now the treatments of choice for all patients. Successful anti-HCV treatment can stop liver disease progression and can solve the HCV-related extra hepatic manifestations, eventually reducing both liver-related and overall mortality. Together with the rapidly accumulating data about the evolution of treatment landscape, different guidelines from national and international Liver Scientific Societies have been published until today. However, these recommendations may not be applied worldwide as, due to high treatment costs, most of them identify as priority groups only patients with advanced liver disease. Moreover some types of patients pose clinical management problems for which even the guidelines do not always provide useful answers. With the aim of treatment optimization by filling some of the gaps of the current guidelines and addressing the remaining unmet needs in practice, a group of Italian experts, experienced on treatment of HCV infection, met in Stresa in February 2016. The summary of all the considerations arising from this two-day meeting and the final statements are reported in this position paper.

Original languageEnglish
Pages (from-to)995-1005
Number of pages11
JournalDigestive and Liver Disease
Volume48
Issue number9
DOIs
Publication statusPublished - Sep 2016

Fingerprint

Hepacivirus
Liver
Chronic Hepatitis C
Virus Diseases
Guidelines
Interferons
Liver Diseases
Therapeutics
Mortality
Health Care Costs
Antiviral Agents
Disease Progression
Public Health
Morbidity

Keywords

  • Antiviral Agents
  • Carcinoma, Hepatocellular
  • Coinfection
  • Drug Therapy, Combination
  • HIV Infections
  • Hepacivirus
  • Hepatitis C, Chronic
  • Humans
  • Interferon-alpha
  • Italy
  • Liver Cirrhosis
  • Liver Neoplasms
  • Practice Guidelines as Topic
  • Ribavirin
  • Societies, Medical
  • Viral Load
  • Journal Article

Cite this

Craxì, A., Perno, C. F., Viganò, M., Ceccherini-Silberstein, F., Petta, S., AdHoc (Advancing Hepatitis C for the Optimization of Cure) Working Party, & Bruno, S. (2016). From current status to optimization of HCV treatment: Recommendations from an expert panel. Digestive and Liver Disease, 48(9), 995-1005. https://doi.org/10.1016/j.dld.2016.06.004

From current status to optimization of HCV treatment : Recommendations from an expert panel. / Craxì, Antonio; Perno, Carlo Federico; Viganò, Mauro; Ceccherini-Silberstein, Francesca; Petta, Salvatore; AdHoc (Advancing Hepatitis C for the Optimization of Cure) Working Party ; Bruno, Savino.

In: Digestive and Liver Disease, Vol. 48, No. 9, 09.2016, p. 995-1005.

Research output: Contribution to journalArticle

Craxì, A, Perno, CF, Viganò, M, Ceccherini-Silberstein, F, Petta, S, AdHoc (Advancing Hepatitis C for the Optimization of Cure) Working Party & Bruno, S 2016, 'From current status to optimization of HCV treatment: Recommendations from an expert panel', Digestive and Liver Disease, vol. 48, no. 9, pp. 995-1005. https://doi.org/10.1016/j.dld.2016.06.004
Craxì A, Perno CF, Viganò M, Ceccherini-Silberstein F, Petta S, AdHoc (Advancing Hepatitis C for the Optimization of Cure) Working Party et al. From current status to optimization of HCV treatment: Recommendations from an expert panel. Digestive and Liver Disease. 2016 Sep;48(9):995-1005. https://doi.org/10.1016/j.dld.2016.06.004
Craxì, Antonio ; Perno, Carlo Federico ; Viganò, Mauro ; Ceccherini-Silberstein, Francesca ; Petta, Salvatore ; AdHoc (Advancing Hepatitis C for the Optimization of Cure) Working Party ; Bruno, Savino. / From current status to optimization of HCV treatment : Recommendations from an expert panel. In: Digestive and Liver Disease. 2016 ; Vol. 48, No. 9. pp. 995-1005.
@article{fcfbbce88154480098ca4ab2c4db8d21,
title = "From current status to optimization of HCV treatment: Recommendations from an expert panel",
abstract = "Chronic hepatitis C virus (HCV) infection is a major public health problem at a global level, causing an enormous burden of hepatic and extra-hepatic morbidity and mortality. Treatment of chronic HCV (CHC) has been revolutionized in the last few years by the introduction of highly effective and well tolerated direct acting antiviral agents (DAAs) able to achieve >90{\%} rates of sustained virological response (SVR) in many groups of patients, including those previously excluded from interferon-based regimens. For such reason interferon-free regimens are now the treatments of choice for all patients. Successful anti-HCV treatment can stop liver disease progression and can solve the HCV-related extra hepatic manifestations, eventually reducing both liver-related and overall mortality. Together with the rapidly accumulating data about the evolution of treatment landscape, different guidelines from national and international Liver Scientific Societies have been published until today. However, these recommendations may not be applied worldwide as, due to high treatment costs, most of them identify as priority groups only patients with advanced liver disease. Moreover some types of patients pose clinical management problems for which even the guidelines do not always provide useful answers. With the aim of treatment optimization by filling some of the gaps of the current guidelines and addressing the remaining unmet needs in practice, a group of Italian experts, experienced on treatment of HCV infection, met in Stresa in February 2016. The summary of all the considerations arising from this two-day meeting and the final statements are reported in this position paper.",
keywords = "Antiviral Agents, Carcinoma, Hepatocellular, Coinfection, Drug Therapy, Combination, HIV Infections, Hepacivirus, Hepatitis C, Chronic, Humans, Interferon-alpha, Italy, Liver Cirrhosis, Liver Neoplasms, Practice Guidelines as Topic, Ribavirin, Societies, Medical, Viral Load, Journal Article",
author = "Antonio Crax{\`i} and Perno, {Carlo Federico} and Mauro Vigan{\`o} and Francesca Ceccherini-Silberstein and Salvatore Petta and {AdHoc (Advancing Hepatitis C for the Optimization of Cure) Working Party} and Savino Bruno",
note = "Copyright {\circledC} 2016. Published by Elsevier Ltd.",
year = "2016",
month = "9",
doi = "10.1016/j.dld.2016.06.004",
language = "English",
volume = "48",
pages = "995--1005",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier B.V.",
number = "9",

}

TY - JOUR

T1 - From current status to optimization of HCV treatment

T2 - Recommendations from an expert panel

AU - Craxì, Antonio

AU - Perno, Carlo Federico

AU - Viganò, Mauro

AU - Ceccherini-Silberstein, Francesca

AU - Petta, Salvatore

AU - AdHoc (Advancing Hepatitis C for the Optimization of Cure) Working Party

AU - Bruno, Savino

N1 - Copyright © 2016. Published by Elsevier Ltd.

PY - 2016/9

Y1 - 2016/9

N2 - Chronic hepatitis C virus (HCV) infection is a major public health problem at a global level, causing an enormous burden of hepatic and extra-hepatic morbidity and mortality. Treatment of chronic HCV (CHC) has been revolutionized in the last few years by the introduction of highly effective and well tolerated direct acting antiviral agents (DAAs) able to achieve >90% rates of sustained virological response (SVR) in many groups of patients, including those previously excluded from interferon-based regimens. For such reason interferon-free regimens are now the treatments of choice for all patients. Successful anti-HCV treatment can stop liver disease progression and can solve the HCV-related extra hepatic manifestations, eventually reducing both liver-related and overall mortality. Together with the rapidly accumulating data about the evolution of treatment landscape, different guidelines from national and international Liver Scientific Societies have been published until today. However, these recommendations may not be applied worldwide as, due to high treatment costs, most of them identify as priority groups only patients with advanced liver disease. Moreover some types of patients pose clinical management problems for which even the guidelines do not always provide useful answers. With the aim of treatment optimization by filling some of the gaps of the current guidelines and addressing the remaining unmet needs in practice, a group of Italian experts, experienced on treatment of HCV infection, met in Stresa in February 2016. The summary of all the considerations arising from this two-day meeting and the final statements are reported in this position paper.

AB - Chronic hepatitis C virus (HCV) infection is a major public health problem at a global level, causing an enormous burden of hepatic and extra-hepatic morbidity and mortality. Treatment of chronic HCV (CHC) has been revolutionized in the last few years by the introduction of highly effective and well tolerated direct acting antiviral agents (DAAs) able to achieve >90% rates of sustained virological response (SVR) in many groups of patients, including those previously excluded from interferon-based regimens. For such reason interferon-free regimens are now the treatments of choice for all patients. Successful anti-HCV treatment can stop liver disease progression and can solve the HCV-related extra hepatic manifestations, eventually reducing both liver-related and overall mortality. Together with the rapidly accumulating data about the evolution of treatment landscape, different guidelines from national and international Liver Scientific Societies have been published until today. However, these recommendations may not be applied worldwide as, due to high treatment costs, most of them identify as priority groups only patients with advanced liver disease. Moreover some types of patients pose clinical management problems for which even the guidelines do not always provide useful answers. With the aim of treatment optimization by filling some of the gaps of the current guidelines and addressing the remaining unmet needs in practice, a group of Italian experts, experienced on treatment of HCV infection, met in Stresa in February 2016. The summary of all the considerations arising from this two-day meeting and the final statements are reported in this position paper.

KW - Antiviral Agents

KW - Carcinoma, Hepatocellular

KW - Coinfection

KW - Drug Therapy, Combination

KW - HIV Infections

KW - Hepacivirus

KW - Hepatitis C, Chronic

KW - Humans

KW - Interferon-alpha

KW - Italy

KW - Liver Cirrhosis

KW - Liver Neoplasms

KW - Practice Guidelines as Topic

KW - Ribavirin

KW - Societies, Medical

KW - Viral Load

KW - Journal Article

U2 - 10.1016/j.dld.2016.06.004

DO - 10.1016/j.dld.2016.06.004

M3 - Article

VL - 48

SP - 995

EP - 1005

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 9

ER -